Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433846 · ClinicalTrials.gov registry record
Predictors of Sepsis in Ex-Preterm Infants
A clinical trial, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 40
- Enrollment target
NCT03433846: Completed study, sponsored by Boston Children's Hospital.
NCT03433846 is a clinical trial that has completed, run by Boston Children's Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03433846 has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The aims of this study are to: * Assess whether ex-preterm infants have a persistently immature immune system, which may decrease their ability to respond to infections, when they reach term-corrected gestational age. * Examine whether clinical history, nutrition status, and microbiome composition are linked to the immune composition of term and ex-preterm infants and whether these variables can be used to predict the risk of developing sepsis or having an immunologic disease.
Primary Outcome
The present study will assess composition and function of T and B cell compartments in preterm and former preterm infants. Whole blood samples will be separated into serum and cellular components and sera will be used to assess cytokine predominance and measure nutritional markers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2022-05-01 |
What the finished NCT03433846 record still lists
NCT03433846 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03433846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03433846 about?
NCT03433846 is a clinical study titled "Predictors of Sepsis in Ex-Preterm Infants". The aims of this study are to: * Assess whether ex-preterm infants have a persistently immature immune system, which may decrease their ability to respond to infections, when they reach term-corrected gestational age. * Examine whether clinical history, nutrition status, and microbiome composition ...
What is the current status of trial NCT03433846?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2019-04-18. Estimated completion is 2022-05-01.
Who is sponsoring clinical trial NCT03433846?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI